Bioxytran (BIXT) Stock Statistics & Valuation Metrics
Total Valuation
Bioxytran has a market cap or net worth of $2.66M. The enterprise value is $4.21T.
- Market Cap
- $2.66M
- Enterprise Value
- $4.21T
Share Statistics
Bioxytran has 114,695,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 114,695,220
- Owned by Insiders
- 1.02%
- Owned by Institutions
- ―
Financial Efficiency
Bioxytran’s return on equity (ROE) is 0.82 and return on invested capital (ROIC) is 138.29%.
- Return on Equity (ROE)
- 0.82
- Return on Assets (ROA)
- -3.22
- Return on Invested Capital (ROIC)
- 138.29%
- Return on Capital Employed (ROCE)
- 0.72
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.06M
- Employee Count
- 2
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Bioxytran is -0.72. Bioxytran’s PEG ratio is -0.01.
- PE Ratio
- -0.72
- PS Ratio
- 0.00
- PB Ratio
- -0.54
- Price to FCF
- -2.65
- Price to Operating Cash Flow
- -3.06
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Bioxytran had revenue of 0 and earned -2.12M in profits. Earnings per share was -0.02.
- Revenue
- 0
- Gross Profit
- -11.54K
- Operating Income
- -1.85M
- Pretax Income
- -2.12M
- Net Income
- -2.12M
- EBITDA
- -1.84M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -866.83K and capital expenditures 0, giving a free cash flow of -866.83K billion.
- Operating Cash Flow
- -866.83K
- Free Cash Flow
- -866.83K
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Bioxytran pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -37.78%
- Earnings Yield
- -131.69%
Stock Price Statistics
- Beta
- -1.52
- 52-Week Price Change
- -67.14%
- 50-Day Moving Average
- 0.02
- 200-Day Moving Average
- 0.03
- Relative Strength Index (RSI)
- 46.62
- Average Volume (3m)
- 103.26K
Financial Position
Bioxytran as a current ratio of 0.16, with Debt / Equity ratio of -48.26%
- Current Ratio
- 0.16
- Quick Ratio
- 0.16
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- -0.40
- Interest Coverage Ratio
- -9.96
Taxes
In the past 12 months, Bioxytran has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Bioxytran EV to EBITDA ratio is -0.93, with an EV/FCF ratio of -3.43.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.93
- EV to Free Cash Flow
- -3.43
- EV to Operating Cash Flow
- -3.43
Balance Sheet
Bioxytran has $177.38K in cash and marketable securities with $855.00K in debt, giving a net cash position of -$677.62K billion.
- Cash & Marketable Securities
- $177.38K
- Total Debt
- $855.00K
- Net Cash
- -$677.62K
- Net Cash Per Share
- -$0.01
- Tangible Book Value Per Share
- -$0.04
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Bioxytran is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -35.29%
